New Delhi: Drugs Controller General of India (DCGI) on Monday approved Biological E’s Covid-19 vaccine Corbevax for emergency use among children aged 12-18 years.
The Hyderabad-based pharmaceutical company’s vaccine had earlier received emergency use authorization from DCGI’s Subject Expert Committee for the 12-18 age group, subject to conditions.
Corbevax, to be administered in two doses, is the third vaccine to be approved for 12-18-year olds in India, the others being Bharat Biotech’s Covaxin and Zydus Cadila’s DNA shot ZyCoV-D.
However, Covaxin is mainly being used currently to inoculate children aged 15-18 years.
Corbevax is expected to cost Rs 145 per dose, excluding taxes, ANI reported quoting sources.
National Technical Advisory Group on Immunisation (NTAGI) chief Dr NK Arora said earlier that Corbevax shots were safe, and offered good immunogenicity and higher antibody levels compared to other vector vaccines.
Sonepur: It was a close shave for seven members of a family when a car…
Jammu: Peoples Democratic Party (PDP) President Mehbooba Mufti has cancelled her election campaign to express…
New Delhi/Bhubaneswar: Prime Minister Narendra Modi on Sunday heaped praises on Ramjit Tudu, a resident…
New Delhi: The death of all members of a family, comprising five individuals, at their…
New Delhi: The Supreme Court on September 30 will hear a batch of public interest…
Bhubaneswar: Bringing cheers for the beneficiaries of Subhadra Yojana, the Odisha government on Sunday announced…
Bhubaneswar: The regional centre of India Meteorological Department (IMD) has issued yellow warning for four…
Chennai: Udhayanidhi Stalin, the 45-year-old son of Tamil Nadu Chief Minister M K Stalin, has…